**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 34011**

**Manuscript type: ORIGINAL ARTICLE**

***Retrospective Study***

**Donor-derived infection among Chinese donated after cardiac death liver recipients**

Ye QF *et al*. Donor-derived infections in liver recipients

Qi-Fa Ye, Wei Zhou, Qi-Quan Wan

**Qi-Fa Ye, Wei Zhou, Qi-Quan Wan,** Department of Transplant Surgery, The Third Xiangya Hospital of Central South University, Changsha 410013, Huna Province, China

**Qi-Fa Ye,** Department of Transplant Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China

**Author contributions:** Wan QQ drafted the manuscript and contributed to the study design and data analysis; Zhou W enrolled the study patients, performed the data collection, and contributed to the data analysis; Ye QF contributed to the study design and data analysis; all authors read and approved the final manuscript.

**Supported by** the New Xiangya Talent Project of The Third Xiangya Hospital of Central South University, No. 20170311.

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board of The Third Xiangya Hospital of Central South University, Changsha, China (IRB No. 2017-S003).

**Conflict-of-interest statement:** All the authors declare they have no conflict of interest related to the manuscript.

**Data sharing statement:** There are no additional data available.

**Open-Access:**This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Qi-Quan Wan, MD, Associate Professor,** Department of Transplant Surgery, The Third Xiangya Hospital of Central South University, No. 138 Tongzipo Road, Changsha 410013, Huna Province, China. [13548685542@163.com](mailto:13548685542@163.com)

**Telephone:** +86-731-88618312

**Fax:** +86-731-88618312

**Received:** march 20, 2017

**Peer-review started:** march 23, 2017

**First decision:** June 5, 2017

**Revised:** June 27, 2017

**Accepted:** July 22, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate blood cultures of deceased donors and report the confirmed transmission of bacterial infection from donors to liver recipients.

***METHODS***

We retrospectively studied the results of blood cultures among our donated after cardiac death (DCD) donors and calculated the donor-derived bacterial infection rates among the liver recipients. Study participants underwent liver transplantation between January 1, 2010 and February 1, 2017. The study involved a total of 67 recipients of liver grafts from 67 DCD donors. We extracted the data of donors’ and patients’ characteristics, culture results and clinical outcomes, especially the post-transplant complications of liver recipients, from electronic medical records. We analyzed the characteristics of the donors and the corresponding liver recipients with donor-derived infections mainly.

***RESULTS***

Head trauma was the most common origin of death among our 67 DCD donors (46.3%). Blood taken prior to the procurement operation was cultured for 53 of the donors, with 17 episodes of bloodstream infections developing from 13 donors. The predominant organism isolated from the blood of donors was Gram-positive bacteria (70.6%). Only 3 of 67 (4.5%) liver recipients developed confirmed donor-derived bacterial infections, with 2 isolates of multidrug-resistant *Klebsiella pneumoniae* and 1 isolate of multidrug-resistant *Enterobacter aerogenes*. The liver recipients with donor-derived infections showed relation to higher crude mortality and graft loss rates (33.3% each) within 3 mo post-transplant, as compared to those without donor-derived infections (9.4% and 4.7%, respectively). All 3 liver recipients received appropriate antimicrobial therapy.

***CONCLUSION***

Liver recipients had high occurrence of donor-derived infections. The liver recipients with donor-derived multidrug-resistant *Enterobacteriaceae* infections can have good outcome if appropriate antimicrobial therapy is given.

**Key words:** Liver transplant; donated after cardiac death donor; Transmission; Infection; Multiple drug resistant; Bacteria

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study aimed to investigate blood cultures of donated after cardiac death (DCD) donors and report the confirmed transmission of bacterial infection from donors to liver recipients. The predominant organism isolated from the blood of donors was Gram-positive bacteria (70.6%). Only 3 of 67 (4.5%) liver recipients developed confirmed donor-derived bacterial infections, with 2 isolates of multidrug-resistant *Klebsiella pneumoniae* and 1 isolate of multidrug-resistant *Enterobacter aerogenes*. Our findings support that liver grafts from DCD donors with bloodstream infections owing to multidrug-resistant *Enterobacteriaceae* can be used if the donors and recipients receive appropriate antimicrobial therapy.

Ye QF, Zhou W, Wan QQ. Donor-derived infection among Chinese donated after cardiac death liver recipients. *World J Gastroenterol*, 2017; In press

**INTRODUCTION**

Liver transplantation is currently considered the therapy of choice for patients with end-stage liver disease. Organs from infected donors after cardiac death (DCD), such as those with bacteremia, are now utilized in response to the disparity between the available graft pool and the organ need for liver transplantation, which carries risk of transmission of infectious diseases and death[1-5]. The risk of unanticipated disease transmission to liver recipients *via* donor grafts has been gaining research attention. Donor-derived transmission of infections remains a rare complication of liver transplantation and the studies have supported its overall safety and favorable outcomes[6-13]; however, the outcome of this type of infection itself among liver recipients is controversial and some authors suggest that it is associated with significant mortality[14,15].

As the volume of liver recipients increases, the number of infections transmitted through DCD donors can also be expected to rise. Unfortunately, the data of DCD donor-derived infections following liver transplantation are currently lacking in China. We, therefore, aimed to investigate the blood cultures of DCD donors and report the cases of confirmed (proven/probable) transmission of bacterial and fungal infections from donors to liver recipients. The current study has provided, to our best knowledge, the first findings of liver recipients experiencing confirmed donor-derived bacterial infections in China and this report represents the largest series of liver recipients with donor-derived infections due to multidrug-resistant (MDR) *Enterobacteriaceae* in the world thus far.

**MATERIALS AND METHODS**

***Study population***

This retrospective analysis of a single-center population was conducted with the purpose of recording all liver recipients with donor-derived bacterial infections. All involved human participants had been initially recruited to the study between January 1, 2010 and February 1, 2017. We then searched the medical record systems of the Third Xiangya Hospital (Changsha, China) to identify all DCD donors and liver recipients among them who donated/received graft from DCD donors. The recorded information allowed for identification of individual participants during or after data collection.

The final study population consisted of 67 liver recipients of grafts from 67 DCD donors who had been admitted into the intensive care unit (ICU) of the Department of Transplant Surgery at the Third Xiangya Hospital of Central South University before organ procurement and transplantation. Multi-organ transplant recipients were excluded from the study. Data recorded included donor age, sex, category, length of ICU stay, number of donors with/without available results of blood cultures, bacteria and fungi isolated from donors, antibiotic administration, and cause of death. The procedures used for donor screening, donor treatment for bacterial and fungal infections and obtainment of the liver graft were also recorded. Liver graft recipient data representing variables associated with donor-derived infection were collected from the medical records as well, and included age, sex, underlying liver diseases, site of infection, time of infection onset, organisms, antimicrobial use, immunosuppressive therapy, and crude mortality/graft loss. The data of post-liver transplant complications were collected for all liver recipients. For all liver graft recipients, the maintenance immunosuppression was tacrolimus/cyclosporin-based complemented with prednisone tapered to 5-10 mg/d. All liver graft recipients were followed-up for at least 3 mo post-transplantation or until death.

***Donor screening and treatment for bacterial and fungal infections***

In our hospital, any DCD donor with a history or suspicion of prior bloodstream infection from whom a liver graft will be harvested is subject to a detailed and appropriate investigation to ensure that infection is not present in the liver. To rule out the presence of active infection, our hospital also takes a complete history from the donor’s family and performs a thorough review of the medical records, including vital signs and findings of physical, radiographic and any available microbiologic tests. Most of the donors in this study also underwent routine culturing of blood, urine and sputum. Blood cultures were obtained to rule out occult donor infection, especially among donors at “increased” risk for bacteremia or fungemia[16]. Targeted antibiotics were administered to the infected donor for at least 24 h, with some degree of clinical response (improved white blood cell count and hemodynamics, defervescence) and, if possible, the infected donor’s treatment included documentation of the infection resolution prior to donation.

***Obtaining liver grafts***

All cases of organ donation were performed according to the protocols for China categories I, II and III donors[17]. After informed consent was obtained from the donor's family, life supports were removed. After the legal 5-min standoff time, the donor immediately underwent a "super-rapid" procurement technique in the operating room. In brief, a rapid abdominal incision was made, followed by rapid cannulation of the abdominal aorta and superior mesenteric or portal vein. The liver was then perfused with University of Wisconsin solution and prompt hepatectomy was performed. The intra-abdominal organs were removed en bloc, submerged in University of Wisconsin solution at 4 °C and placed in cold storage. The bile duct was flushed with physiological saline solution *in situ* and preserved *ex situ* by University of Wisconsin solution.

***Recipient prophylactic strategies and treatment for bacterial and fungal infections***

Second- or third-generation cephalosporins, semisynthetic penicillins/beta-lactamase inhibitors, or car­bapenems, were prescribed according to the pre-transplant results of cultures and administered 1 h before the liver transplan­tation, with an additional dose given at 72 h post-transplantation to the liver recipients without donor-derived infection. Recipients of liver graft from a bacteremic donor were treated with a 7-d to 14-d course of targeted antibiotics. Antifungal therapy was administered within 2 wk to a recipient of liver graft from a donor with fungemia if the liver recipient had no evidence of infection. Cases of established fungal infection were administered a 4-wk to 6-wk course, with at least 6 wk of treatment, when vascular involvement was present.

***Definitions***

The deceased-organ donations were classified as follows: China category I (C-I): Organ donation after brain death; China category II (C-II): Organ donation after circulatory death; China category III (C-III): Organ donation after brain death followed by circulatory death[17].

Transmission of organisms was considered proven by clear evidence of the same infection in the donor and at least one of the recipients. Transmission of the organisms was considered probable by strong evidence suggesting but not proving infectious transmission, such as the infection being documented in more than one recipient but not diagnosed in the donor[18]. Both proven and probable transmissions were considered as confirmed transmission of infections[18]. Appropriate antimicrobial use in donors was considered when the infected donor had received targeted antimicrobial treatment for at least 24-48 h, optimally with some degree of clinical response[19]. Appropriate antimicrobial use in recipients was considered if the isolated organisms showed *in vitro* susceptibility to empirical antibiotics, which were administered within 48 h of sampling for culture[20].

We utilized the standardized definition of MDR *Enterobacteriaceae*, as previously defined by international consensus in 2012; specifically, MDR was considered with evidence of non-susceptibility to at least one agent in three or more appointed antimicrobial categories[21].

**RESULTS**

***DCD donor characteristics***

There were 67 liver recipients of graft from 67 DCD donors during the study period. The characteristics of the donors are shown in Table 1. The DCD donors showed a male-dominated sex ratio (nearly 1:4) and were largely represented by young adults. The pre-retrieval ICU length of stay ranged from 1 d up to 41 d. Head trauma was the most common cause of death, followed by central nervous system benign tumor. The majority of donors were classified as China category III, followed by China category III.

***Cases of infectious transmission from DCD donors to liver graft recipients***

For 53 of the donors (79.1%), the blood samples taken prior to the procurement operation were cultured and produced evidence of 17 bloodstream infections from 13 of the donors. Appropriate antimicrobial use, according to the positive blood culture results, was administered in 10 of those 13 donors. The results of blood cultures from the donors are shown in Table 2. The majority of pathogens isolated from the donor's blood were coagulase-negative *Staphylococci*. Among the 3 donors who elicited infectious transmission to 3 liver recipients, 1 donor did not have an available result of blood culture and the other 2 donors had negative results of blood culture after being admitted to the ICU; none of these 3 donors underwent blood culture within 10 d prior to organ procurement.

***Infectious agents transmitted from DCD donors to liver graft recipients***

Table 3 shows the characteristics of these 3 donors (D1-D3) and their corresponding liver recipients (R1-R3, representing 4.5% of the total recipient population), highlighting the relationship between donors and recipients with infection transmission. Several cultures (blood, urine, and abdominal drainage fluid) were routinely taken from the recipients following the liver transplantation. The confirmed donor-derived MDR bacterial infections included 2 isolates of *Klebsiella pneumoniae* and 1 isolate of *Enterobacter aerogenes*. Both of the *Klebsiella pneumoniae* isolates were extended-spectrum beta lactamase-producing rods. All 3 of the isolates (all being *Enterobacteriaceae* family members) were carbapene-susceptible.

***Recipient characteristics and outcomes of infectious transmissions from DCD donors to liver graft recipients***

Additional isolates from 4 recipients of kidney graft from these 3 donors (D1-D3) provided strong evidence of transmission of infectious bacteria through their similar resistance profiles. Thus, no recipient case of infection transmission could be classified as a proven donor-derived infection, and all 3 cases (R1-R3) were classified as probable donor-derived infections. No liver recipients developed donor-derived fungal infections. No recipients had a presumed or confirmed invasive bacterial or fungal infection pre-transplantation. The underlying liver diseases of these 3 recipients were polycystic liver disease, hepatocellular carcinoma and cirrhosis due to hepatitis B virus infection, and heredofamilial amyloidosis. All 3 donor-derived infections occurred within 3 d post-transplantation, and were administered appropriate anti-microbial therapy prior to or immediately following diagnosis of the infection. All 3 recipients recovered from the donor-derived bacterial infections, but 1 died of septic shock with graft loss owing to other organisms. Liver recipients without donor-derived infections had lower rates of crude mortality and graft loss (6/64, 9.4% and 3/64, 4.7% respectively) within 3 mo post-transplantation, as compared with those with donor-derived infections (33.3% each).

***Post-liver transplant complications in liver graft recipients with and without DCD-derived infection***

All complications experienced by the full liver recipient population (*n* = 67) are presented in Table 4. The most common complication was post-transplant infection; the 20 total infections occurred in the 3 liver recipients with donor-derived infection (4 infection episodes) and the 64 liver recipients without donor-derived infection (16 infection episodes). The next most common complication was vascular (9 vascular episodes), all cases of which occurred in the liver recipients without donor-derived infection. Tumor recurrence developed in 6 of the liver recipients without donor-derived infection and none of the recipients with donor-derived infection.

***Survival of liver graft recipients with and without DCD-derived infection***

Figure 1 shows the Kaplan-Meier curves for 3-mo survival after liver transplantation. There was no difference in survival between the liver recipients with and without donor-derived infection (log-rank test, *P* = 0.165).

**DISCUSSION**

Although there are numerous reports of fatal donor-derived infection affecting around 3% of solid organ transplants, in the current era of organ shortage marginal organ donors are increasingly utilized[22,23]. More recent data demonstrate that most bacterial isolates appear to be irrelevant to subsequent recipient outcome and that the grafts from bacteremic donors may be safely used if bacteremia in the donor has been ideally treated and antibiotic therapy is continued in the organ recipient[2,6,7,24,25].

Our present study found 19.4% (13/67) of donors having available results of blood cultures developed bloodstream infections, which is in line with literature reports suggesting that about 5%-11.3% of all deceased donors have unrecognized bacteremia at the time of donation[2,6,8,25]. We also found that 3 (4.5%) of 67 donors transmitted bacterial infections to 3 liver recipients, which agrees with the 2013 report[26] from the Organ Procurement and Transplantation Network Ad Hoc disease transmission advisory committee that reported 15 out of 117 (12.8%) donors with infections developed proven/probable transmission of bacterial (except for tuberculosis) and fungal infections.

Doucette *et al*[3] proposed that the observed higher risk of transmission in liver recipients, as compared to other solid organ recipients, may be mainly attributed to bacterial retention in and poor antibiotic penetration of the liver graft. Some recipient-related factors were also proposed, such as a high Model for End-Stage Liver Disease (commonly known as MELD) score, leukopenia, and immunosuppression.

Coagulase-negative *Staphylococci* (such as *Staphylococcus epidermidis*) and *Staphylococcus aureus* represent the more commonly isolated microorganisms from donor blood cultures[7,8,25]. In our donor blood cultures, the majority of isolates were coagulase-negative *Staphylococci* and *S. aureus* (together 70.6%; 12 of 17 pathogens)*.* Coagulase-negative *Staphylococci* also represent the most common microorganisms isolated from preservation fluid[2,15,27]. None of the cases of donor-derived infections in liver recipients of our study were due to Gram-positive bacteria, agreeing with previous studies that have suggested lower risk of transmission of Gram-positive bacteria (*vs* Gram-negative bacteria) from a donor to a recipient[6,28-30]. This could be due to several reasons, such as low pathogenicity of coagulase-negative *Staphylococci*, potential contaminant in donor culture (*i.e*. not a true pathogen), or catheter line-associated in donor (*i.e*. not systemic infection).

All 3 donor-derived infections in our current study were caused by MDR Gram-negative bacteria, agreeing with a previous report suggesting that Gram-negative bacteria account for about 80% of transmissions to recipients[9]. Although rare, donor-derived infection caused by bacteria, in particular MDR bacteria, can have devastating consequences for organ transplant recipients[9-11,29,31]. The data reported to the United States’ Organ Procurement and Transplantation Network from 2005 to 2011 showed the donor-derived infection-attributable recipient mortality rate to be 29.2% (19/65)[6]. These previous studies were consistent with our present study, wherein 1 (33.3%) of 3 liver recipients with MDR *K. pneumoniae* infection died related to subsequent septic shock due to other organisms and the rate of graft loss was 33.3%. In contrast with our finding, however, others have reported a favorable outcome among liver recipients with donor-derived infections due to MDR Gram-negative bacteria or methicillin-resistant *S. aureus* (commonly known as MRSA)[3,5,9-11,23,32-34]. Further data are needed to assess the effects of donor-derived bacterial or fungal infections and appropriate antimicrobial use on allograft function and recipient survival over a long-term follow-up period.

The current study has provided, to the best of our knowledge, the first data of liver recipients with confirmed donor-derived bacterial infections treated in a single transplant center in China; in addition, the report represents the largest of liver recipients with donor-derived infections due to MDR *Enterobacteriaceae* in the world thus far. Since both the morbidity and mortality rates of donor-derived infection are high in China, the findings from the current study support future efforts towards a better understanding of potential risks for disease transmission and highlight the necessity for a standardized critical incident reporting system in the Chinese transplant system to improve short- and long-term allograft and recipient survival.

The principal limitation of our study was the single-center, retrospective study design, which did not allow for the investigation of donor-derived MDR bacterial infections by genetic or molecular analysis. Improvements in new screening technologies, such as the use of whole genome sequencing, have recently proven a powerful advance in the investigation of donor-derived MDR bacterial infections[35]. Since we used drug-sensitive test screening for donor-derived infection rather than a gene-level technique, it is possible that our testing algorithm over-estimated the transmission events.

Nonetheless, our findings underscore the importance of blood culture being performed as close to the donation time as possible and the importance of testing preservation fluid culture; since the reported contamination rates of the latter range widely (from 9.5% to 98.4%)[2,15,27], this sample was not routinely obtained at our institution. Our findings also indicate that donors with infections should receive antibiotics directed at the identified bacteria or fungi 24-48 h prior to procurement, optimally yielding evidence of clinical improvement.

In conclusion, DCD donors in our institute had high rate of bacterial infection, with Gram-positive bacteria being the predominant isolate, whereas the donor-derived infections developed by liver recipients were Gram-negative predominant. Our findings strongly supported organ donation as the common source of bacterial infection in the liver recipients. Although the number of these cases in our study was too small to draw conclusions, we support the use of liver grafts from the DCD donor pool, including those with infections owing to MDR *Enterobacteriaceae* if the donors and recipients receive appropriate antimicrobial therapy.

**COMMENTS**

***Background***

Nowadays, the use of bacteremic donors to fulfill the disparity between the limited donor pool and the increasing need for organs is an expanding practice, which may result in an increased risk of transmission of infectious diseases and death. However, the data of donated after cardiac death (DCD) donor-derived infections following liver transplantation are currently lacking in China. As limited data are available in Chinese liver recipients of grafts from DCD donors, this study aimed to investigate the blood cultures of DCD donors and report the cases of confirmed (proven/probable) transmission of bacterial and fungal infections from donors to liver recipients.

***Research frontiers***

The use of infectious donors to fulfill the disparity between the limited donor pool and the increasing need for organs has become an important issue in the field of transplantation. Furthermore, the use of donors with infections caused by multidrug-resistant (MDR) bacteria is controversial and the recipients with MDR infections have a high mortality. This study shows excellent outcome for liver recipients with donor-derived MDR infections.

***Innovations and breakthroughs***

This is the first study to analyze liver recipients experiencing confirmed donor-derived bacterial infections in China and the largest report of liver recipients with donor-derived infections due to MDR *Enterobacteriaceae* in the world thus far.

***Applications***

Liver grafts from the pool of DCD donors with bloodstream infections owing to MDR *Enterobacteriaceae* can be used if the donors have been treated and have documentation of resolution of infection prior to donation, and if the corresponding liver recipients are treated with a 7- to 14-d course of antibiotics targeted to the organism isolated from a bacteremic donor.

***Terminology***

Confirmed transmission includes a proven or probable transmission. A proven transmission was indicated by clear evidence of the same infectious disease in the donor and at least one of the recipients. A probable transmission was indicated by strong evidence suggesting, but not proving, a disease transmission, such as the disease being documented in more than one recipient but not being diagnosed in the donor. MDR bacteria was defined as non-susceptibility to at least one agent in three or more appointed antimicrobial categories.

***Peer-review***

Though sample size was small, this paper provides important information. This report shows excellent outcomes for recipients with donor-derived infections.

**REFERENCES**

1 **Wolfe RA**, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. *Am J Transplant* 2010; **10**: 961-972 [PMID: 20420646 DOI: 10.1111/j.1600-6143.2010.03021.x]

2 **Cerutti E**, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, Mascia L, Lupo F, Franchello A, Panio A, Salizzoni M. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. *Liver Transpl* 2006; **12**: 1253-1259 [PMID: 16724336 DOI: 10.1002/lt.20811]

3 **Doucette KE**, Al-Saif M, Kneteman N, Chui L, Tyrrell GJ, Kumar D, Humar A. Donor-derived bacteremia in liver transplant recipients despite antibiotic prophylaxis. *Am J Transplant* 2013; **13**: 1080-1083 [PMID: 23398841 DOI: 10.1111/ajt.12133]

4 **Camargo JF**. Donor-derived infections in solid organ transplant recipients: Challenging the 30-day paradigm. *Transpl Infect Dis* 2017; **19**: [PMID: 28100037 DOI: 10.1111/tid.12665]

5 **Miceli MH**, Gonulalan M, Perri MB, Samuel L, Al Fares MA, Brown K, Bruno DA, Zervos M, Ramesh M, Alangaden G. Transmission of infection to liver transplant recipients from donors with infective endocarditis: lessons learned. *Transpl Infect Dis* 2015; **17**: 140-146 [PMID: 25586791 DOI: 10.1111/tid.12330]

6 **Ison MG**, Grossi P; AST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation. *Am J Transplant* 2013; **13 Suppl 4**: 22-30 [PMID: 23464995 DOI: 10.1111/ajt.12095]

7 **Freeman RB**, Giatras I, Falagas ME, Supran S, O'Connor K, Bradley J, Snydman DR, Delmonico FL. Outcome of transplantation of organs procured from bacteremic donors. *Transplantation* 1999; **68**: 1107-1111 [PMID: 10551637]

8 **Lumbreras C**, Sanz F, González A, Pérez G, Ramos MJ, Aguado JM, Lizasoain M, Andrés A, Moreno E, Gómez MA, Noriega AR. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. *Clin Infect Dis* 2001; **33**: 722-726 [PMID: 11477528 DOI: 10.1086/322599]

9 **Mularoni A**, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, Gruttadauria S, Vitulo P, Conaldi P, Luca A, Gridelli B, Grossi P. Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria. *Am J Transplant* 2015; **15**: 2674-2682 [PMID: 25981339 DOI: 10.1111/ajt.13317]

10 **Mills JP**, Wilck MB, Weikert BC, Porrett PM, Timko D, Alby K, Bonomo RA, Blumberg EA. Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen. *Transpl Infect Dis* 2016; **18**: 777-781 [PMID: 27458980 DOI: 10.1111/tid.12578]

11 **Ariza-Heredia EJ**, Patel R, Blumberg EA, Walker RC, Lewis R, Evans J, Sankar A, Willliams MD, Rogers J, Milano C, Razonable RR. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. *Transpl Infect Dis* 2012; **14**: 229-236 [PMID: 22624726 DOI: 10.1111/j.1399-3062.2012.00742.x]

12 **Zibari GB**, Lipka J, Zizzi H, Abreo KD, Jacobbi L, McDonald JC. The use of contaminated donor organs in transplantation. *Clin Transplant* 2000; **14**: 397-400 [PMID: 10946778]

13 **Cohen J**, Michowiz R, Ashkenazi T, Pitlik S, Singer P. Successful organ transplantation from donors with Acinetobacter baumannii septic shock. *Transplantation* 2006; **81**: 853-855 [PMID: 16570007 DOI: 10.1097/01.tp.0000203804.95180.6e]

14 **van der Vliet JA**, Tidow G, Kootstra G, van Saene HF, Krom RA, Sloof MJ, Weening JJ, Tegzess AM, Meijer S, van Boven WP. Transplantation of contaminated organs. *Br J Surg* 1980; **67**: 596-598 [PMID: 7000231]

15 **Janny S**, Bert F, Dondero F, Durand F, Guerrini P, Merckx P, Nicolas-Chanoine MH, Belghiti J, Mantz J, Paugam-Burtz C. Microbiological findings of culture-positive preservation fluid in liver transplantation. *Transpl Infect Dis* 2011; **13**: 9-14 [PMID: 20738832 DOI: 10.1111/j.1399-3062.2010.00558.x]

16 **Fischer SA**, Lu K; AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. *Am J Transplant* 2013; **13 Suppl 4**: 9-21 [PMID: 23464994 DOI: 10.1111/ajt.12094]

17 **Huang J**, Wang H, Fan ST, Zhao B, Zhang Z, Hao L, Huo F, Liu Y. The national program for deceased organ donation in China. *Transplantation* 2013; **96**: 5-9 [PMID: 23743728 DOI: 10.1097/TP.0b013e3182985491]

18 **Garzoni C**, Ison MG. Uniform definitions for donor-derived infectious disease transmissions in solid organ transplantation. *Transplantation* 2011; **92**: 1297-1300 [PMID: 21996654 DOI: 10.1097/TP.0b013e318236cd02]

19 **Fishman JA**, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. *Clin Infect Dis* 2012; **55**: 720-727 [PMID: 22670038 DOI: 10.1093/cid/cis519]

20 **Gao F**, Ye Q, Wan Q, Liu S, Zhou J. Distribution and resistance of pathogens in liver transplant recipients with Acinetobacter baumannii infection. *Ther Clin Risk Manag* 2015; **11**: 501-505 [PMID: 25848296 DOI: 10.2147/TCRM.]

21 **Magiorakos AP**, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012; **18**: 268-281 [PMID: 21793988 DOI: 10.1111/j.1469-0691.2011.03570.x]

22 **Kirchner VA**, Pruett TL. Receiving the Unwanted Gift: Infection Transmission through Organ Transplantation. *Surg Infect (Larchmt)* 2016; **17**: 318-322 [PMID: 27096745 DOI: 10.1089/sur.2016.009]

23 **Altman DR**, Sebra R, Hand J, Attie O, Deikus G, Carpini KW, Patel G, Rana M, Arvelakis A, Grewal P, Dutta J, Rose H, Shopsin B, Daefler S, Schadt E, Kasarskis A, van Bakel H, Bashir A, Huprikar S. Transmission of methicillin-resistant Staphylococcus aureus via deceased donor liver transplantation confirmed by whole genome sequencing. *Am J Transplant* 2014; **14**: 2640-2644 [PMID: 25250641 DOI: 10.1111/ajt.12897]

24 **Goldberg E**, Bishara J, Lev S, Singer P, Cohen J. Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report. *Transpl Infect Dis* 2012; **14**: 296-299 [PMID: 22176504 DOI: 10.1111/j.1399-3062.2011.00697.x]

25 **González-Segura C**, Pascual M, García Huete L, Cañizares R, Torras J, Corral L, Santos P, Ramos R, Pujol M. Donors with positive blood culture: could they transmit infections to the recipients? *Transplant Proc* 2005; **37**: 3664-3666 [PMID: 16386498 DOI: 10.1016/j.transproceed.2005.08.053]

26 **Green M**, Covington S, Taranto S, Wolfe C, Bell W, Biggins SW, Conti D, DeStefano GD, Dominguez E, Ennis D, Gross T, Klassen-Fischer M, Kotton C, LaPointe-Rudow D, Law Y, Ludrosky K, Menegus M, Morris MI, Nalesnik MA, Pavlakis M, Pruett T, Sifri C, Kaul D. Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee. *Transplantation* 2015; **99**: 282-287 [PMID: 25594557 DOI: 10.1097/TP.0000000000000584]

27 **Ruiz P**, Gastaca M, Gonzalez J, Hernandez MJ, Ventoso A, Valdivieso A, Montejo M, Ortiz de Urbina J. Incidence and clinical relevance of bacterial contamination in preservation solution for liver transplantation. *Transplant Proc* 2009; **41**: 2169-2171 [PMID: 19715863 DOI: 10.1016/j.transproceed.2009.06.036]

28 **Sifri CD**, Ison MG. Highly resistant bacteria and donor-derived infections: treading in uncharted territory. *Transpl Infect Dis* 2012; **14**: 223-228 [PMID: 22676635 DOI: 10.1111/j.1399-3062.2012.00752.x]

29 **Watkins AC**, Vedula GV, Horan J, Dellicarpini K, Pak SW, Daly T, Samstein B, Kato T, Emond JC, Guarrera JV. The deceased organ donor with an "open abdomen": proceed with caution. *Transpl Infect Dis* 2012; **14**: 311-315 [PMID: 22283979 DOI: 10.1111/j.1399-3062.2011.00712.x]

30 **Bull DA**, Stahl RD, McMahan DL, Jones KW, Hawkins JA, Renlund DG, Taylor DO, Karwande SV. The high risk heart donor: potential pitfalls. *J Heart Lung Transplant* 1995; **14**: 424-428 [PMID: 7654726]

31 **Martins N**, Martins IS, de Freitas WV, de Matos JA, Magalhães AC, Girão VB, Dias RC, de Souza TC, Pellegrino FL, Costa LD, Boasquevisque CH, Nouér SA, Riley LW, Santoro-Lopes G, Moreira BM. Severe infection in a lung transplant recipient caused by donor-transmitted carbapenem-resistant Acinetobacter baumannii. *Transpl Infect Dis* 2012; **14**: 316-320 [PMID: 22168176 DOI: 10.1111/j.1399-3062.2011.00701.x]

32 **Wendt JM**, Kaul D, Limbago BM, Ramesh M, Cohle S, Denison AM, Driebe EM, Rasheed JK, Zaki SR, Blau DM, Paddock CD, McDougal LK, Engelthaler DM, Keim PS, Roe CC, Akselrod H, Kuehnert MJ, Basavaraju SV. Transmission of methicillin-resistant Staphylococcus aureus infection through solid organ transplantation: confirmation via whole genome sequencing. *Am J Transplant* 2014; **14**: 2633-2639 [PMID: 25250717 DOI: 10.1111/ajt.12898]

33 **Johnston L**, Chui L, Chang N, Macdonald S, McKenzie M, Kennedy W, Haldane D, Bethune R, Taylor G, Hanakowski M, Tyrrell G. Cross-Canada spread of methicillin-resistant Staphylococcus aureus via transplant organs. *Clin Infect Dis* 1999; **29**: 819-823 [PMID: 10589896 DOI: 10.1086/520442]

34 **Giani T**, Conte V, Mandalà S, D'Andrea MM, Luzzaro F, Conaldi PG, Grossi P, Rossolini GM. Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor. *J Clin Microbiol* 2014; **52**: 2702-2705 [PMID: 24759725 DOI: 10.1128/JCM.00511-14]

35 **Fishman JA**, Grossi PA. Donor-derived infection--the challenge for transplant safety. *Nat Rev Nephrol* 2014; **10**: 663-672 [PMID: 25178971 DOI: 10.1038/nrneph.2014.159]

**P-Reviewer:** Boin IFSF, Hori T, Inoue K **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Kaplan-Meier curves for 3-mo survival after liver transplantation.** \*Log-rank test indicated no significant difference in survival among the two groups.

**Table 1 Characteristics of 67 donated after cardiac death donors** ***n* (%)**

|  |  |
| --- | --- |
| **Characteristic** | **Value** |
| Age in years, median (IQR) | 29.0 (19.0-44.0) |
| Sex, |  |
| Male | 55 (82.1) |
| Female | 12 (17.9) |
| Origin of death |  |
| HT | 31 (46.3) |
| CNS benign tumor | 18 (26.9) |
| CVA | 15 (22.4) |
| Anoxia | 2 (3.0) |
| Meningitis | 1 (1.5) |
| China classification of donation |  |
| I | 5 (7.5) |
| II | 8 (11.9) |
| III | 54 (80.6) |
| ICU stay in days, median (IQR) | 5 (3.0-10.0) |
| Donors with positive culture | 13 |
| Blood culture, *n*/*n* |  |
| Donors with/without available results | 53/14 |
| Donors with appropriate antimicrobial use/all donors with positive blood culture results | 10/13 |

CNS: Central nervous system; CVA: Cerebrovascular accident; DCD: Donated after cardiac death; HT: Head trauma; ICU: Intensive care unit; IQR, Interquartile range.

**Table 2 Classification and percentage of organisms isolated from donors' bloodstream, *n*=17**

|  |  |  |
| --- | --- | --- |
| **Organism** | ***n*** | (**%**) |
| Gram-positive bacteria | 12 | (70.6) |
| *Staphylococcus aureus* | 3 | (17.6) |
| Coagulase-negative *Staphylococci* | 9 | (52.9) |
| *S. epidermidis* | 4 | (23.5) |
| *S. hemolyticus* | 1 | (5.9) |
| *S. capitis* | 1 | (5.9) |
| *S. hominis* | 2 | (11.8) |
| *S. simulans* | 1 | (5.9) |
| Gram-negative bacteria | 3 | (17.6) |
| *Klebsiella pneumoniae* | 2 | (11.8) |
| *Acinetobacter baumannii* | 1 | (5.9) |
| Fungi | 2 | (11.8) |
| *Candida albicans* | 1 | (5.9) |
| *Candida parapsilosis* | 1 | (5.9) |

**Table 3 Characteristics of donors and their corresponding liver recipients with donor-derived infections**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Donor** | **Diagnosis** | **Blood culture result** | **Recipient (sex/age)** | **Underlying liver diseases** | **Culture result (specimen)/Time to infection onset** | **Inappropriate antimircotic/immunosuppresive** | **Outcome** |
| D1 | Head trauma | Negative1 | R12 (Female/48 yr) | Polycystic liver disease | *K. pneumoniae* (Blood and abdominal drainage fluid)/1 d | No/Pred | Patient death and graft loss |
| D2 | Head trauma | Negative1 | R23 (Male/38 yr) | Hepatocellular carcinoma and cirrhosis due to hepatitis B virus infection | *K. pneumoniae* (Blood and abdominal drainage fluid)/1 d | No/FK506 + Pred | Patient and graft survival |
| D3 | Head trauma | Not available | R33 (Male/69 yr) | Heredofamilial amyloidosis | *E. aerogenes* (Blood)/3 d | No/FK506 + Pred | Patient and graft survival |

1Donors had a negative result of blood culture after being admitted to the intensive care unit, whereas they did not undergo blood culture within 10 d prior to organ procurement; 2Two kidney recipients of graft from the common donor, with this liver recipient having developed organ-space surgical site infection owing to *Klebsiella pneumoniae* within 20 d following the transplantation; 3One kidney recipient of graft from the common donor, with this liver recipient having also developed bloodstream infection owing to the same bacterium immediately after the transplantation.

**Table 4 Comparison of post-liver-transplant complications of liver recipients with donor-derived infections and without**

|  |  |  |
| --- | --- | --- |
| **Complication** | **Episodes of complications in 3 liver recipients with donor-derived infection** | **Episodes of complications in 64 liver recipients without donor-derived infection** |
| Infection | 4 | 16 |
| Pneumonia | 1 | 7 |
| Peritonitis | 0 | 3 |
| Bloodstream infection | 3 | 5 |
| Surgical site | 0 | 1 |
| Vascular complications | 0 | 9 |
| Portal vein thrombosis | 0 | 1 |
| Cerebral embolism | 0 | 1 |
| Hepatic artery thrombosis | 0 | 1 |
| Abdominal bleeding | 0 | 5 |
| Gastrointestinal bleeding | 0 | 1 |
| Biliary complications | 3 | 2 |
| Bile leakage | 0 | 0 |
| Biliary strictures | 1 | 2 |
| Stone formation | 1 | 0 |
| Bilomas | 1 | 0 |
| Recurrent tumor | 0 | 6 |
| Acute rejection | 0 | 4 |
| Graft-versus-host disease | 0 | 2 |
| Graft dysfunction | 0 | 3 |
| Adhesive ileus | 0 | 1 |